Commercialization Challenges for Advanced Oncology Modalities

This technical report discusses the commercialization challenges faced by advanced modalities such as cell and gene therapies and radiopharmaceuticals in the oncology sector. It outlines insights from the Commercializing Uphill panel at the Cancer Progress 2025 meeting, emphasizing that the barriers to commercialization are systemic rather than scientific. The report highlights the need for evolving commercialization models to match the rapid advancements in science. It details the complexities involved in delivering these therapies, including manufacturing limitations, clinic preparedness, and investor hesitance. The discussion includes perspectives from industry leaders who stress that successful commercialization requires not only scientific efficacy but also viable pathways for scaling therapies. The report concludes with recommendations for addressing these challenges, including the importance of early commercialization planning and the necessity for coordinated changes across scientific, business, and health systems to ensure that innovative therapies reach patients effectively.